Cambrex Corp. is discontinuing its acquisition program aimed at transforming the company into a specialty therapeutics enterprise, due to the increasing cost to acquire companies in this sector and the risk of achieving an appropriate return on investment. The company has decided to concentrate its resources on its Bioproducts segment and capitalize on its cell biology, molecular biology, rapid microbial testing and cell therapy manufacturing. The Human Health and Biopharma segments will “...